Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.

Erasmus MC/Sophia Children's Hospital, Pediatric Oncology/Hematology, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands.
Blood (Impact Factor: 9.78). 09/2005; 106(5):1817-23. DOI: 10.1182/blood-2004-11-4296
Source: PubMed

ABSTRACT Drug resistance in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with impaired ability to induce apoptosis. To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10). PARP expression was present in all B-lineage samples, but absent in 4 of 15 T-lineage ALL samples and 3 of 10 AML cases, which was not caused by genomic deletions. PARP expression was a median 7-fold lower in T-lineage ALL (P < .001) and 10-fold lower in AML (P < .001) compared with B-lineage ALL. PARP expression was 4-fold lower in prednisolone, vincristine and L-asparaginase (PVA)-resistant compared with PVA-sensitive ALL patients (P < .001). Procaspase-2 expression was 3-fold lower in T-lineage ALL (P = .022) and AML (P = .014) compared with B-lineage ALL. In addition, procaspase-2 expression was 2-fold lower in PVA-resistant compared to PVA-sensitive ALL patients (P = .042). No relation between apoptotic protease-activating factor 1 (Apaf-1), procaspases-3, -6, -7, -8, -10, and drug resistance was found. In conclusion, low baseline expression of PARP and procaspase-2 is related to cellular drug resistance in childhood acute lymphoblastic leukemia.


Available from: Ka M Kazemier, Aug 19, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Programmed cell death plays a central role in the regulation of homeostasis and development of multicellular organisms. Deregulation of programmed cell death is connected to a number of disorders, including cancer and autoimmune diseases. Initiation of cell death occurs in the multiprotein complexes or high molecular weight platforms. Composition, structure, and molecular interactions within these platforms influence the cellular decision toward life or death and, therefore, define the induction of a particular cell death program. Here, we discuss in detail the key cell-death complexes-including DISC, complex II, and TNFRI complex I/II, and the necrosome, RIPoptosome, apoptosome, and PIDDosome-that control apoptosis or necroptosis pathways as well as their regulation. The possibility of their pharmacological targeting leading to the development of new strategies of interference with cell death programs via control of the high molecular weight platforms will be discussed.
    Cellular and Molecular Life Sciences CMLS 10/2014; 72(3). DOI:10.1007/s00018-014-1757-2 · 5.86 Impact Factor
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Apoptosis (programmed cell death) is essential process in multicellular organisms. Apoptosis plays an important role in cell differentiation, damaged cell elimination, and immune system homeostasis. The review focuses on various mechanisms of signal transduction through caspase-2, which is thought to be one of the most enigmatic proteases involved in apoptosis. Caspase-2 is activated upon stimulation by various factors, including genotoxic stress, death receptor ligation, endoplasmic reticulum stress, metabolic changes, and a number of others. In addition, caspase-2 can act as a tumor suppressor and has been implicated in the cell response to oxidative stress and neurodegenerative progression during ischemic brain injury. Thus, the variety of pathways triggered by caspase-2 sets the enzyme apart from other members of the family and suggests a prominent role in apoptosis. The review analyzes the various functions of this unique caspase and discusses the possible applications of the available knowledge about it in modern oncology and medicine.
    Molecular Biology 03/2013; 47(2). DOI:10.1134/S0026893313010020 · 0.74 Impact Factor